Roche Half-Year Report 2022

• Group sales up 5% at constant exchange rates (CER) and 5% in Swiss francs
• Pharmaceuticals Division sales increase 3%; continued strong demand for new medicines to treat severe diseases; as expected, the impact of biosimilars slows down further
• Diagnostics Division sales grow 11%; ongoing strong base business; demand for COVID-19 tests is expected to decline in the second half of the year
• IFRS net income increases by 12% (12% in Swiss francs), while core earnings per share are up 11%

Highlights in the second quarter:

• • EU approvals of Polivy (first-line treatment for aggressive form of blood cancer), Lunsumio (follicular lymphoma) and Tecentriq (early-stage lung cancer); EU marketing authorisation application submitted for glofitamab (blood cancer)
  • US approval of Evrysdi (babies under two months of age with spinal muscular atrophy) and US priority review for Lunsumio
  • Launch of innovative platforms and systems for tissue-based cancer diagnostics, of HPV self sampling solution and monkeypox virus test kits

Pharmaceuticals sales: selected top-selling and new medicines

Tecentriq (first approved in 2016; CHF 1.8 billion, +11%). Cancer immunotherapy (either alone or in combinations) for various types of cancer, e.g. lung, bladder, breast and liver cancer. Sales increased mostly due to higher demand in the United States and Europe. Sales in Japan decreased, primarily due to governmental price cuts.